Valbiotis Share Price

ALVAL

FR0013254851

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 15:03:19 07/08/2026 BST			5-day change	1st Jan Change
0.8230 ^EUR	+4.18%		+6.88%	+18.59%

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT

Analysts' recommendations: Valbiotis

05-12	Valbiotis shares surge on Asian expansion plans
30/10/24	Valbiotis: Invest Securities reduces its target
17/07/23	Valbiotis: Invest Securities confirms its recommendation
25/05/23	Valbiotis: Oddo BHF raises its target price
23/05/23	Valbiotis: promising study, Invest Sec. raises its target

More recommendations

News in other languages: Valbiotis

07-27	VALBIOTIS SA: Loi sur la prévention cardiovasculaire : Une réponse à un enjeu de santé public majeur Une avancée en pleine cohérence avec la mission de Valbiotis
07-22	VALBIOTIS SA: Les résultats de l’étude clinique REVERSE-IT publiés dans Nature Communications, une reconnaissance scientifique internationale majeure pour l’ingrédient Totum•63
07-22	VALBIOTIS SA: Bilan semestriel du contrat de liquidité.
06-29	Bourse : Ipsen rachète Kartos, Google et Meta se chicanent, Samsung et SK investissent
06-29	Le marché prend une partie de ses bénéfices sur l'IA

More news

Managers and Directors: Valbiotis

Manager	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Stanislas Sordet DFI	Director of Finance/CFO	-	29/02/2024
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	31/08/2017

Director	Title	Age	Since
Laurent Lévy CHM	Chairman	55	28/02/2017
Jean Zetlaoui BRD	Director/Board Member	-	25/10/2017
Agnès Tixier BRD	Director/Board Member	-	17/03/2019

More insiders

VALBIOTIS is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, VALBIOTIS offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-12 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	€0.8230	+4.18%	172,994
06/08/26	€0.7900	+0.64%	61,943
05/08/26	€0.7850	+2.48%	87,293
04/08/26	€0.7660	+1.46%	90,727
03/08/26	€0.7550	-1.95%	94,519

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7900EUR

Average target price

1.800EUR

Spread / Average Target

+127.85%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Stock Market
Stocks
ALVAL Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	18.69M 21.54M 17.5M 16.01M 30.22M 2.05B 30.62M 205M 80.35M 1.03B 80.86M 79.1M 3.41B	P/E 2026 *	-3.43x	P/E 2027 *	-9.88x
Enterprise Value	24.59M 28.34M 23.02M 21.06M 39.76M 2.7B 40.28M 269M 106M 1.35B 106M 104M 4.49B	EV / Sales 2026 *	7.93x	EV / Sales 2027 *	2.31x
Free-Float	97.31%	Yield 2026 *	-	Yield 2027 *	-

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT
06-26	Valbiotis successfully completes a €10.2m capital increase
06-08	Valbiotis Secures Exclusive Distributor in Qatar	MT
06-08	Valbiotis and Al Danah Medical Company Signs Exclusive Distribution Agreement for Valbiotispro Range in Qatar	CI
06-08	Valbiotis strengthens Middle East presence through Qatar partnership
05-27	Valbiotis SA Announces EU Member States Vote in Favor of Regulation Banning Monacolins From Red Yeast Rice	CI
05-12	Valbiotis shares surge on Asian expansion plans
05-12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
05-11	Valbiotis and Aika Form Joint Venture and Establish Subsidiary in Singapore	CI
05-11	Pluxee, Lacroix, Valbiotis... stocks to watch tomorrow in Paris
05-11	Valbiotis continues Asian expansion with the establishment of a Singapore subsidiary
05-11	Valbiotis announces creation by Chinese JV of subsidiary in Singapore	RE

07-27	VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission	EQ
07-22	VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63	EQ
06-26	VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M	EQ
06-08	VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%	EQ
06-08	VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East	EQ

1 day	+4.18%
1 week	+6.88%
Current month	+6.88%
1 month	+2.24%
3 months	-13.73%
6 months	-26.52%
Current year	+18.59%

1 week	0.74	0.85
1 month	0.74	0.85
Current year	0.65	1.3
1 year	0.54	1.3
3 years	0.54	7.5
5 years	0.54	7.5
10 years	0.54	10.65

Valbiotis Share Price

Stocks

ALVAL

FR0013254851

Biotechnology & Medical Research

Valuation: Valbiotis

Chart: Valbiotis

Latest news : Valbiotis

Analysts' recommendations: Valbiotis

Press Releases: Valbiotis

News in other languages: Valbiotis

Quotes and Performance

Course Extremes

Managers and Directors: Valbiotis

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/01/22	Jocelyn Pineau	Others	Founder	42,480	0.4364%
28/01/22	Jocelyn Pineau	Fiscal year	Founder	2,095	0.0215%
10/07/21	Pascal Sirvent	Fiscal year	Chief Technology Officer	2,000	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALBIOTIS	+4.18%	+6.88%	-0.48%	-79.83%	21.54M
WUXI APPTEC CO., LTD.	-3.25%	+13.72%	+52.49%	+88.86%	62.92B
ARGENX SE	+1.64%	+2.93%	+33.17%	+73.44%	54.32B
BIONTECH SE	+1.64%	+2.34%	-16.75%	-5.89%	22.91B
INSMED INCORPORATED	-2.84%	+31.57%	+18.69%	+493.16%	28.73B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	21.65B
GENMAB A/S	+7.30%	+9.60%	+40.82%	-19.83%	17.76B
PHARMAESSENTIA CORPORATION	-3.37%	+25.85%	+213.21%	+369.13%	16.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	15.48B
EXELIXIS, INC.	+1.93%	+1.16%	+43.47%	+164.91%	13.12B
Average	+2.43%	+7.50%	+47.23%	+177.04%	25.34B
Weighted average by Cap.	+1.08%	+8.61%	+46.37%	+166.38%

	2026 *	2027 *
Net sales	3.1M 3.57M 2.9M 2.66M 5.01M 340M 5.08M 33.96M 13.33M 170M 13.41M 13.12M 566M	12.8M 14.75M 11.99M 10.96M 20.7M 1.41B 20.97M 140M 55.03M 702M 55.38M 54.18M 2.34B
Net income	-8.2M -9.45M -7.68M -7.02M -13.26M -900M -13.43M -89.83M -35.25M -450M -35.48M -34.71M -1.5B	-2.8M -3.23M -2.62M -2.4M -4.53M -307M -4.59M -30.67M -12.04M -154M -12.11M -11.85M -511M
Net Debt	5.9M 6.8M 5.52M 5.05M 9.54M 648M 9.67M 64.63M 25.36M 324M 25.53M 24.97M 1.08B	10.9M 12.56M 10.21M 9.34M 17.63M 1.2B 17.86M 119M 46.86M 598M 47.16M 46.13M 1.99B